Key Points
- Jamie Dananberg sold 5,290 Annexon shares on Feb. 18 at an average price of $5.10 for total proceeds of $26,979, reducing his stake to 73,152 shares (a 6.74% drop); the sale was disclosed in an SEC Form 4 filing.
- Several other executives — including EVPs Michael Overdorf, Ted Yednock, Dean Artis and CFO Jennifer Lew — also sold shares at roughly $5.10 in the same period, indicating notable insider selling across management.
- ANNX traded near $4.90 (52-week range $1.28–$7.18) with a market cap of about $586M; analysts have a consensus rating of Moderate Buy (average target $17) and Wells Fargo recently raised its target to $27.
Annexon, Inc. (NASDAQ:ANNX - Get Free Report) insider Jamie Dananberg sold 5,290 shares of Annexon stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $5.10, for a total transaction of $26,979.00. Following the completion of the transaction, the insider owned 73,152 shares of the company's stock, valued at $373,075.20. This represents a 6.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Annexon Stock Performance
ANNX stock traded down $0.20 during midday trading on Friday, reaching $4.90. 1,749,100 shares of the company's stock traded hands, compared to its average volume of 1,986,881. Annexon, Inc. has a 52 week low of $1.28 and a 52 week high of $7.18. The company has a 50-day moving average price of $5.58 and a two-hundred day moving average price of $3.94. The firm has a market capitalization of $586.19 million, a PE ratio of -3.48 and a beta of 1.17.
Analyst Ratings Changes
Several research analysts have commented on the company. Wells Fargo & Company raised their target price on Annexon from $14.00 to $27.00 and gave the stock an "overweight" rating in a research note on Wednesday, November 19th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Annexon in a research note on Wednesday, January 21st. Chardan Capital began coverage on shares of Annexon in a report on Tuesday, December 23rd. They set a "buy" rating and a $16.00 target price on the stock. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Annexon in a report on Wednesday, January 14th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $17.00.
Get Our Latest Research Report on Annexon
More Annexon News
Here are the key news stories impacting Annexon this week:
- Neutral Sentiment: Short-interest reports for Feb. 19–20 show 0 shares of reported short interest and a 0.0 days-to-cover metric — this appears to be a data/reporting anomaly (NaN changes). The readings do not indicate meaningful new short activity to explain the move. Short Interest Report
- Negative Sentiment: EVP Michael Overdorf sold 6,225 shares at an average $5.10 (≈$31.7k); his holdings fell ~4.8%. Form 4 - Overdorf
- Negative Sentiment: EVP Ted Yednock sold 7,857 shares at an average $5.11 (≈$40.1k); his position dropped ~7.5%. Form 4 - Yednock
- Negative Sentiment: EVP Dean Richard Artis sold 5,290 shares at an average $5.10 (≈$27.0k); his holding decreased ~4.1%. Form 4 - Artis
- Negative Sentiment: CFO Jennifer Lew sold 7,851 shares at an average $5.11 (≈$40.1k); her stake fell ~6.5%. Form 4 - Lew
- Negative Sentiment: Insider Jamie Dananberg sold 5,290 shares at an average $5.10 (≈$27.0k); his holding declined ~6.7%. Form 4 - Dananberg
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the company. Invesco Ltd. raised its position in Annexon by 381.5% during the fourth quarter. Invesco Ltd. now owns 972,449 shares of the company's stock valued at $4,882,000 after purchasing an additional 770,504 shares in the last quarter. Mercer Global Advisors Inc. ADV bought a new position in shares of Annexon during the 4th quarter valued at about $52,000. XTX Topco Ltd raised its holdings in shares of Annexon by 64.6% during the 4th quarter. XTX Topco Ltd now owns 243,313 shares of the company's stock valued at $1,221,000 after buying an additional 95,473 shares in the last quarter. Ikarian Capital LLC bought a new stake in Annexon in the 4th quarter worth approximately $1,156,000. Finally, Virtus Investment Advisers LLC boosted its stake in Annexon by 27.5% in the fourth quarter. Virtus Investment Advisers LLC now owns 53,527 shares of the company's stock worth $269,000 after buying an additional 11,540 shares in the last quarter.
About Annexon
(
Get Free Report)
Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company's research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.
At the core of Annexon's pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
